Cortisol in Oncology: An Emerging Area of Scientific Inquiry

Cortisol in Oncology: An Emerging Area of Scientific Inquiry

Progress in oncology has historically come from many scientific directions. Some advances stem from broad exploration across multiple therapeutic pathways, while others result from sustained investigation into a single biological mechanism. Both approaches have contributed to meaningful improvements in patient care, underscoring the importance of diverse research strategies in advancing the field.

One area gaining increased attention is the intersection of stress biology and oncology—specifically, the role of cortisol and the glucocorticoid receptor (GR) in cancer development and treatment response. Once considered largely peripheral to tumor biology, this pathway is now being examined more closely for its potential influence on tumor survival, therapeutic resistance, and patient outcomes.²

The Role of Cortisol and the Glucocorticoid Receptor

Cortisol is a vital hormone involved in regulating immune function, metabolism, and the body’s response to stress. Under normal physiological conditions, its actions help maintain homeostasis. In oncology, however, cortisol signaling can have unintended consequences.¹

Cortisol exerts its effects primarily through activation of the glucocorticoid receptor, which is expressed in nearly all tissues, including many tumor types and immune cells. When activated, the GR translocates to the nucleus and regulates genes involved in cell survival and stress adaptation, including SGK1 and DUSP1, which promote resistance to apoptosis—the primary mechanism through which many anticancer therapies act. Cortisol signaling also suppresses immune activity by reducing pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), potentially weakening anti-tumor immune responses and contributing to treatment resistance.^3,4

Preclinical studies across multiple epithelial cancers demonstrate that GR activation can blunt the effectiveness of commonly used treatments, including platinum-based chemotherapies and taxanes, by protecting tumor cells from programmed cell death.^3,4 These findings illustrate a complex biological paradox: a hormone essential for normal health may also activate pathways that allow cancer cells to evade treatment.

Clinical observations further support this relationship. In ovarian cancer, for example, administration of glucocorticoids such as dexamethasone has been shown to rapidly increase SGK1 and DUSP1 expression in tumor tissue, which may decrease chemotherapy effectiveness in patients through increased anti-apoptotic gene expression.⁶

Clinical Implications of GR Signaling

As understanding of GR biology evolves, its relevance to oncology practice is becoming clearer. Glucocorticoids such as dexamethasone are widely used in cancer care to manage nausea, inflammation, hypersensitivity reactions, and cerebral edema. While these agents play an important supportive role, emerging evidence suggests their interaction with tumor biology warrants closer consideration.^2,4

Recognizing how GR signaling may influence treatment response could inform more nuanced clinical decision-making—particularly in settings where therapeutic resistance limits options. Researchers are exploring whether antagonism of this pathway may help restore or enhance sensitivity to therapies in select patient populations, including platinum-resistant ovarian cancer.³ This approach reflects a growing effort to better understand how supportive care and tumor biology intersect.

Toward a More Integrated View of Cancer Care

The study of cortisol and GR signaling reinforces the importance of holistic, medically integrated oncology care. Cancer treatment does not occur in isolation; it is shaped by supportive medications, stress physiology, and the broader care environment. Integrating insights from molecular biology, pharmacology, and supportive care can help clinicians better anticipate how different aspects of treatment interact.

GR expression has been documented across a wide range of solid tumors, including ovarian, renal cell, cervical, sarcoma, and melanoma, underscoring the broad relevance of this pathway in oncology.^4,7 As oncology continues to move toward more personalized and biologically informed care, interdisciplinary collaboration will be essential to translating these insights into clinical practice.

Looking Ahead

Ongoing research into cortisol and GR signaling is expanding understanding of how this pathway can influence cancer biology. Future studies will help determine how these insights may be incorporated into treatment strategies, supportive care practices, or clinical guidelines.

Equally important is ensuring that emerging science is translated responsibly—balancing innovation with evidence and patient safety. As new findings continue to emerge, education and collaboration across the oncology community will remain critical to advancing care.

Article Sponsored by: